Skip to main content

Advertisement

SpringerLink
Log in

Intraocular pressure effect of anti-vascular endothelial growth factor injection for aggressive posterior retinopathy of prematurity

  • Pediatrics
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the effect of 0.0125 mL and 0.025 mL doses of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection on intraocular pressure (IOP) in eyes with aggressive posterior retinopathy of prematurity (ROP).

Methods

In this retrospective cohort study, charts of 52 eyes of 26 consecutive infants were reviewed. The patients received 0.0125 mL (Group 1) or 0.025 mL (Group 2) anti-VEGF agents’ intravitreally. The IOP was measured before injection, on the first day, during the first week, and in the first month. After each injection, optic nerve head perfusion was evaluated by a binocular indirect ophthalmoscope. IOP values, complications, use of antiglaucomatous drops, and the effects of anti-VEGF drugs were recorded.

Results

The mean baseline IOP before injection was 16.0 ± 3.7 mmHg for Group 1 and 15.5 ± 4.5 mmHg for Group 2 (p = 0.365). The mean value of IOP on the first day was statistically increased in Group 2 (29.2 ± 6.1 mmHg) compared with Group 1 (24.1 ± 6.8 mmHg) (p = 0.013). Moreover, antiglaucomatous drops were needed in 12 eyes for Group 2 compared with seven eyes for Group 1. Anterior chamber paracentesis was not performed after any of the injections.

Conclusion

This study found that IOP increases after intravitreal injections of anti-VEGF agents for the treatment of ROP. The injection of 0.025 mL anti-VEGF agents increases IOP more than the 0.0125 mL injection in the treatment of infants with aggressive posterior ROP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Code availability

Not applicable.

References

  1. Terry TL (1946) Retrolental fibroplasia. J Pediatr 29:770–773. https://doi.org/10.1016/s0022-3476(46)80009-x

    Article  CAS  PubMed  Google Scholar 

  2. Fierson WM, Academy A, of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists, (2018) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 142:e20183061. https://doi.org/10.1542/peds.2018-381

    Article  PubMed  Google Scholar 

  3. Quinn GE (2016) Retinopathy of prematurity blindnesss worldwide: phenotypes in the third epidemic. Eye Brain 8:31–36. https://doi.org/10.2147/EB.S94436

    Article  PubMed  PubMed Central  Google Scholar 

  4. Mintz-Hittner, HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615. https://doi.org/10.1056/NEJMoa1007374

    Article  Google Scholar 

  5. Drenser KA, Trese MT, Capone A Jr (2010) Aggressive posterior retinopathy of prematurity. Retina 30:S37–S40. https://doi.org/10.1097/IAE.0b013e3181cb6151

    Article  PubMed  Google Scholar 

  6. Sankar MJ, Sankar J, Chandra P (2018) Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 1(1):CD009734. https://doi.org/10.1002/14651858.CD009734.pub2

    Article  PubMed  Google Scholar 

  7. Erol MK, Coban DT, Sari ES, Bilgin AB, Dogan B, Ozdemir O, Tunay ZO (2015) Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol 78:340–343. https://doi.org/10.5935/0004-2749.20150090

    Article  PubMed  Google Scholar 

  8. Sukgen EA, Gunay M, Kocluk Y (2017) Occurrence of intraocular air bubbles during intravitreal injections for retinopathy of prematurity. Int Ophthalmol 37:215–219. https://doi.org/10.1007/s10792-016-0257-9

    Article  PubMed  Google Scholar 

  9. Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, Wu WC (2016) Neurodevelopmental outcomes of infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE 11:e0148019. https://doi.org/10.1371/journal.pone.0148019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sacchi M, Lizzio RAU, Villani E, Monsellato G, Lucentini S, Cremonesi E, Luccarelli S, Serafino M, Nucci P (2020) Medical management of pediatric glaucoma: lessons learned from randomized clinical trials. Graefes Arch Clin Exp Ophthalmol 258(8):1579–1586. https://doi.org/10.1007/s00417-020-04767-9

    Article  CAS  PubMed  Google Scholar 

  11. International Committee for the Classification of Retinopathy of Prematurity (2005) The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 123:991–999. https://doi.org/10.1001/archopht.123.7.991

    Article  Google Scholar 

  12. Azad R, Chandra P (2005) Retinopathy of prematurity. J Indian Med Assoc 103:370–372

    PubMed  Google Scholar 

  13. Kara C, Hekimoglu E, Petricli IS, Akıl H (2017) Intravitreal bevacizumab as rescue therapy following treatment failure with laser photocoagulation in retinopathy of prematurity. J Curr Ophthalmol 30:80–84. https://doi.org/10.1016/j.joco.2017.08.007

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ozdemir O, Ozen Tunay Z, Ozdek S, Erginturk Acar D (2016) The exudative retinal detachment after laser photocoagulation and its treatment in a case of retinopathy of prematurity. Ret-Vit 24:70–73

    Google Scholar 

  15. Chandra P, Tewari R, Salunkhe N, Kumawat D, Kumar V (2017) Giant retinal tear with retinal detachment in regressed aggressive posterior retinopathy of prematurity treated by laser. J Pediatr Ophthalmol Strabismus 54:e34–e36. https://doi.org/10.3928/01913913-20170531-01

    Article  PubMed  Google Scholar 

  16. Ozdemir O, Ozen Tunay Z, Erginturk Acar D, Ozmen MC (2017) A case with bilateral anterior segment ischemia, hypotonia and cataract following the treatment for retinopathy of prematurity. Turkiye Klinikleri J Ophthalmol 26:210–214. https://doi.org/10.5336/ophthal.2015-48256

    Article  Google Scholar 

  17. Shapiro MJ, Blair MP, Gonzalez JMG (2017) Aggressive posterior retinopathy of prematurity (APROP). In: Kychenthal BA, Dorta SP (eds) Retinopathy of prematurity. Springer, Cham, pp 49–70

    Chapter  Google Scholar 

  18. Menke MN, Framme C, Nelle M, Berger MR, Sturm V, Wolf S (2015) Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol 15:20. https://doi.org/10.1186/s12886-015-0001-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Obata S, Higashiyama T, Imamura T, Kakinoki M, Yanagi T, Maruo Y, Ohji M (2019) Short-term changes in intraocular pressure after intravitreal injection of bevacizumab for the treatment of retinopathy of prematurity. Clin Ophthalmol 13:2445–2449. https://doi.org/10.2147/OPTH.S229708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kato A, Okamoto Y, Okamoto F, Saito M, Miyazono Y, Oshika T (2019) Short-term intraocular pressure changes after intravitreal injection of bevacizumab for retinopathy of prematurity. Jpn J Ophthalmol 63:262–268. https://doi.org/10.1007/s10384-019-00661-y

    Article  CAS  PubMed  Google Scholar 

  21. Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN (2013) An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol 155:150-158.e1. https://doi.org/10.1016/j.ajo.2012.06.010

    Article  CAS  PubMed  Google Scholar 

  22. Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE (2013) Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 98:F170–F174. https://doi.org/10.1136/archdischild-2011-301148

    Article  PubMed  Google Scholar 

  23. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P (2009) Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 18:658–661. https://doi.org/10.1097/IJG.0b013e31819c4893

    Article  PubMed  Google Scholar 

  24. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N (2009) Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 40:293–295. https://doi.org/10.3928/15428877-20090430-12

    Article  PubMed  Google Scholar 

  25. Benz MS, Albini TA, Holz ER, Lakhanpal RR, Westfall AC, Iyer MN, Carvounis PE (2006) Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 113:1174–1178. https://doi.org/10.1016/j.ophtha.2005.10.06

    Article  PubMed  Google Scholar 

  26. Cacciamani A, Oddone F, Parravano M, Scarinci F, Di Nicola M, Lofoco G (2013) Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol 57:63–67. https://doi.org/10.1007/s10384-012-0194-8

    Article  CAS  PubMed  Google Scholar 

  27. Kampougeris G, Spyropoulos D, Mitropoulou A (2013) Intraocular pressure rise after anti-vegf treatment: prevalence, possible mechanisms and correlations. J Curr Glaucoma Pract 7:19–24. https://doi.org/10.5005/jp-journals-10008-1132

    Article  PubMed  PubMed Central  Google Scholar 

  28. Hartnett ME, Gilbert MM, Richardson TM, Krug JH Jr, Hirose T (1990) Anterior segment evaluation of infants with retinopathy of prematurity. Ophthalmology 97:122–130. https://doi.org/10.1016/s0161-6420(90)32637-4

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey

    Ozdemir Ozdemir

  2. Department of Ophthalmology, Ankara City Hospital, Ankara, Turkey

    Aysegul Arman

  3. Division of Neonatology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey

    Cuneyt Tayman

Authors
  1. Ozdemir Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aysegul Arman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cuneyt Tayman
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Ozdemir Ozdemir, Aysegul Arman, and Cuneyt Tayman. The first draft of the manuscript was written by Ozdemir Ozdemir and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ozdemir Ozdemir.

Ethics declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ankara City Hospital Ethical Committee (No. E1/736/2020).

Consent to participate

Written informed consent was obtained from the parents.

Consent for publication

Parents of patients signed informed consent regarding publishing their data and photographs.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ozdemir, O., Arman, A. & Tayman, C. Intraocular pressure effect of anti-vascular endothelial growth factor injection for aggressive posterior retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 259, 3469–3476 (2021). https://doi.org/10.1007/s00417-021-05278-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-021-05278-x

Keywords

Search

Navigation